Cumberland Pharmaceuticals CPIX Change in unpaid invoices for offering costs
Change in unpaid invoices for offering costs at other companies
Other financials
Where this comes from
Reported directly by Cumberland Pharmaceuticals in its filing.
Tagged under the XBRL concept cpix:ChangeInUnpaidInvoicesForOfferingCosts.
The official record: Cumberland Pharmaceuticals’s 10-K, filed March 9, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cumberland Pharmaceuticals's change in unpaid invoices for offering costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cumberland Pharmaceuticals's change in unpaid invoices for offering costs?
- Cumberland Pharmaceuticals (CPIX) reported change in unpaid invoices for offering costs of $15.5 in Q4 2025.
- How has Cumberland Pharmaceuticals's change in unpaid invoices for offering costs changed year-over-year?
- Cumberland Pharmaceuticals's change in unpaid invoices for offering costs increased by 100.1% year-over-year, from -$17.43K to $15.5.
- What is the long-term trend for Cumberland Pharmaceuticals's change in unpaid invoices for offering costs?
- Over 3 years (2022 to 2025), Cumberland Pharmaceuticals's change in unpaid invoices for offering costs has grown at a -91.3% compound annual growth rate (CAGR), from -$94.69K to $62.
- What does change in unpaid invoices for offering costs mean?
- Reflects the change in accrued liabilities for costs associated with equity or debt offerings, such as legal, accounting, and underwriting fees. This metric helps investors understand the timing of cash payments for capital-raising activities relative to when the costs were incurred. It is useful for assessing the efficiency of capital market transactions.